NITRIC-OXIDE AND SUPEROXIDE RADICAL ARE INVOLVED IN BOTH INITIATION AND DEVELOPMENT OF ADJUVANT ARTHRITIS IN RATS

被引:28
作者
OYANAGUI, Y
机构
[1] Drug Develop. Lab., Fujisawa Pharmaceut. Co., Yodogawa-ku, Osaka, 532
关键词
ADJUVANT ARTHRITIS; NITRIC OXIDE SYNTHASE INHIBITORS; SUPEROXIDE DISMUTASE; VOLTAREN(R);
D O I
10.1016/0024-3205(94)00858-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Nitric oxide synthase(NOS) inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME, 10-300 mg/kg) and L-N(G)-monomethyl-arginine (L-NMMA, 30-300 mg/kg) suppressed the swellings of adjuvant-injected paw of rats (25-54%) at day 2 and 8 when dosed intraperitoneally and orally for 4 days from day -1 to day 2 after adjuvant. L-NAME (30-300 mg/kg) also suppressed the edema of the non adjuvant-injected paws (15-42%) at day 28. Local injection of this inhibitor (2 and 10 mg/kg) was without effect. L-arginine (1 g/kg, i.p.), impaired the suppression by L-NAME. Bovine blood Cu, Zn-superoxide dismutase (SOD, 3 mg/kg, i.p.: 28% suppression) and L-NAME (30 mg/kg i.p.: 36% suppression) showed additive effect (52%) in adjuvant-injected paws at day 8 when co-injected. As the effect of 30 mg/kg L-NAME corresponded nearly to that of 10 mg/kg Voltaren(R), this NOS inhibitor would be worth considering as an anti-inflammatory agent. Sodium nitroprusside (NO-donor) and methylene blue (guanylate cyclase inhibitor) had no effect. L-NAME was also suppressive when dosed after adjuvant inoculation and NO is involved in the development and maintenance of swelling.
引用
收藏
页码:PL285 / PL289
页数:5
相关论文
共 16 条
[1]   NITRIC-OXIDE SYNTHASE INHIBITORS ATTENUATE HUMAN MONOCYTE CHEMOTAXIS INVITRO [J].
BELENKY, SN ;
ROBBINS, RA ;
RUBINSTEIN, I .
JOURNAL OF LEUKOCYTE BIOLOGY, 1993, 53 (05) :498-503
[2]  
DING AH, 1988, J IMMUNOL, V141, P2407
[3]   EVIDENCE THAT ENDOGENOUS NITRIC-OXIDE MODULATES EDEMA FORMATION INDUCED BY SUBSTANCE-P [J].
HUGHES, SR ;
WILLIAMS, TJ ;
BRAIN, SD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 191 (03) :481-484
[4]   MODULATION OF ACUTE-INFLAMMATION BY ENDOGENOUS NITRIC-OXIDE [J].
IALENTI, A ;
IANARO, A ;
MONCADA, S ;
DIROSA, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 211 (02) :177-182
[5]  
Jadot G, 1986, Free Radic Res Commun, V2, P27, DOI 10.3109/10715768609088053
[6]   NITRIC-OXIDE TAKES CENTER-STAGE WITH NEWLY DEFINED ROLES [J].
MCCALL, T ;
VALLANCE, P .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (01) :1-6
[7]   SUPPRESSION OF ARTHRITIS BY AN INHIBITOR OF NITRIC-OXIDE SYNTHASE [J].
MCCARTNEYFRANCIS, N ;
ALLEN, JB ;
MIZEL, DE ;
ALBINA, JE ;
XIE, QW ;
NATHAN, CF ;
WAHL, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :749-754
[8]  
MONCADA S, 1991, PHARMACOL REV, V43, P109
[9]   PROTECTIVE EFFECTS OF INHIBITORS OF NITRIC-OXIDE SYNTHASE IN IMMUNE COMPLEX-INDUCED VASCULITIS [J].
MULLIGAN, MS ;
MONCADA, S ;
WARD, PA .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (04) :1159-1162
[10]   ENDOTHELIUM-DERIVED RELAXING FACTOR CONTRIBUTES TO THE REGULATION OF ENDOTHELIAL PERMEABILITY [J].
OLIVER, JA .
JOURNAL OF CELLULAR PHYSIOLOGY, 1992, 151 (03) :506-511